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RESEARCH ARTICLE
Enhancing the toolbox to study IL-17A 
in cattle and sheep
Sean R. Wattegedera1* , Yolanda Corripio‑Miyar1,2 , Yvonne Pang1, David Frew1, Tom N. McNeilly1 , 
Javier Palarea‑Albaladejo3, Colin J. McInnes1 , Jayne C. Hope2 , Elizabeth J. Glass2  and Gary Entrican1,2 
Abstract 
The development of methods to detect cytokine expression by T cell subsets in ruminants is fundamental to strate‑
gic development of new livestock vaccines for prevention of infectious diseases. It has been possible to detect T cell 
expression of IFN‑γ, IL‑4 and IL‑10 in ruminants for many years but methods to detect expression of IL‑17A are rela‑
tively limited. To address this gap in capability we have cloned bovine and ovine IL‑17A cDNAs and expressed biolog‑
ically‑active recombinant proteins in Chinese Hamster Ovary (CHO) cells. We used the transfected CHO cells to screen 
commercially‑available antibodies for their ability to detect IL‑17A expression intracellularly and in culture supernates. 
We demonstrate that an ELISA for bovine IL‑17A detects native ovine IL‑17A. Moreover, the constituent polyclonal 
antibodies (pabs) in the ELISA were used to enumerate peripheral blood mononuclear cells (PBMC) expressing IL‑17A 
from cattle and sheep by ELISpot. We identified two monoclonal antibodies (mabs) that detect recombinant intracel‑
lular IL‑17A in CHO cells by flow cytometry. One of these mabs was used to detect native intracellular IL‑17A expres‑
sion in PBMC in conjunction with cell surface phenotyping mabs [CD4+ve, CD8+ve and Workshop Cluster 1 (WC‑
1)+ve gamma‑delta (γδ)] we show that distinct T cell subsets in cattle (defined as CD4+ve, CD8+ve or WC‑1+ve) and 
sheep (defined as CD4+ve or WC‑1+ve) can express IL‑17A following activation. These novel techniques provide a 
solid basis to investigate IL‑17A expression and define specific CD4+ve T cell subset activation in ruminants.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Interleukin(IL)-17 was first described in 1993 as a novel 
transcript in a T cell hybridoma clone and named cyto-
toxic T lymphocyte associated antigen 8 (CTLA-8) [1]. 
It was subsequently renamed IL-17A and it is one of the 
IL-17 family of six related homodimeric cytokines [IL-
17A, -B, -C, -D, -E (also known as IL-25) and -F] that are 
involved in acute and chronic inflammatory responses in 
humans and murine models as reviewed by Gu et al. [2]. 
IL-17A is the “signature cytokine” secreted by the Th-17 
CD4+ve T cell subset [3]. Activation of Th-17-type 
responses are important not only for host immune con-
trol of extracellular bacterial and fungal infections but are 
also associated with chronic inflammation and autoim-
munity. Detailed knowledge of IL-17A biology in humans 
has led to the targeted development of immunotherapeu-
tic monoclonal antibodies (mabs) to block IL-17A and 
the IL-17RA receptor for the treatment and control of 
psoriasis, multiple sclerosis and rheumatoid arthritis [4].
However, as for many immunological parameters, our 
knowledge of IL-17A production and its function in vet-
erinary species is very limited compared to humans and 
biomedical rodent models [5] despite cloning of bovine 
IL-17A in 2006 [6]. In farmed ruminant species, there are 
published studies that measure mRNA encoding bovine 
IL-17 family members. These include IL-17A expres-
sion in purified protein derivative-stimulated peripheral 
blood mononuclear cells (PBMC) from cattle with mac-
roscopic lung lesion pathology following experimental 
Mycobacterium bovis infection [7]; IL-17A and IL-17F 
in afferent lymph cells in response to liposomal vaccine 
preparations [8]; and IL-17A, IL-17C, IL-17E and IL-17F 
in the udder of lactating cows infected with Escherichia 
coli [9]. Measurement of IL-17 family members at the 
protein level in ruminant species has been limited by the 
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paucity of species-specific reagents with the exception of 
one commercially-available ELISA kit to detect bovine 
IL-17A (Kingfisher Biotech). Using this ELISA, Flynn 
et al. [10] have shown the capacity of Neospora caninum-
infected bovine macrophages to stimulate IL-17A pro-
duction in naive CD4+ve T cells while Tassi et  al. [11] 
have shown the presence of IL-17A in milk from lactating 
cattle infected by Streptococcus uberis.
The detection and biological function of other IL-17 
family members in ruminants is less well characterised. 
Bougarn et al. [12] and Roussel et al. [9] reported the up-
regulation of mRNA encoding the chemokines CCL2 and 
CCL20 in primary bovine mammary epithelial cells by 
recombinant bovine IL-17A and IL-17F, consistent with 
activities of the human and rodent orthologues. In 2011, 
Gossner et al. [13] sequenced two variant IL-17E (IL-25) 
sequences from ovine gastric lymph nodes. Most of the 
cattle, sheep and goat IL-17 family sequences have been 
published (Additional file  1) but only recombinant IL-
17A is commercially available at present for all three spe-
cies, with IL-17F also available for cattle. To improve our 
capability to study IL-17A biology in sheep and cattle we 
have screened a panel of commercial antibodies for abil-
ity to recognise recombinant bovine and ovine IL-17A 
expressed in mammalian cells and further evaluated their 
performance in a range of techniques for detection of the 
native cytokine in T cell subsets.
Materials and methods
Animals
Four Texel-cross ewes of approximately 3 years of age, six 
Greyface ewes 2–4 years of age and three male Holstein–
Friesian cattle 8–12  months of age were maintained off 
pasture by the Bioservices Division at Moredun Research 
Institute (MRI) in helminth-free conditions. In addition, 
four female Holstein–Friesian cattle of approximately 
2  years of age were maintained off pasture at Dryden 
Farm, The Roslin Institute (RI) at The University of Edin-
burgh. All animal procedures were approved by the Eth-
ics Committees at MRI and RI and performed to Home 
Office Guidelines under Project Licences PPL 60/4394, 
PPL 60/3854, PPL 60/4380 and PPL 60/4391. Venous 
blood was collected into heparinised vacutainers (Bec-
ton–Dickinson, Oxford, UK) or into syringes containing 
sodium heparin (final concentration 20  U/mL, Sigma-
Aldrich, Dorset, UK). PBMC were isolated from hep-
arinised sheep and cattle blood by density centrifugation 
using established protocols [14] and used for molecu-
lar cloning, mitogen re-stimulation assays and ELISpot 
assays. For analysis of cytokine expression by specific T 
cell subsets, an additional red blood cell lysis step was 
applied to the PBMC following density centrifugation 
using a lysis buffer containing 10 mM  KHCO3, 150 mM 
 NH4Cl, 0.1 mM EDTA pH 8.0 for 5 min at room temper-
ature (RT).
Cloning, sequencing and bioinformatic analyses of IL‑17A
We have observed that Concanavalin A (ConA) stimu-
lates ruminant PBMC and found it very effective at 
upregulating mRNA expression of inflammatory (IFN-
γ) and regulatory (IL-10) cytokines from 6 to 96  h [15] 
and considered this time-frame ideal for acquiring tem-
plate cDNA for bovine and ovine IL-17A. PBMC from 
one male calf (male Holstein–Friesian) and one ewe 
(Texel-cross) were seeded into six-well flat bottom plates 
(Corning Costar, Scientific Laboratory Supplies Ltd, 
Coatbridge, UK) at a concentration of 1 ×  106 cells/mL 
in RPMI-1640 (Gibco, Life Technologies, Paisley, UK) 
supplemented with 0.1% 2-mercaptoethanol (Sigma-
Aldrich), 1% l-glutamine and 10% heat-inactivated fetal 
bovine serum (FBS, Gibco) and stimulated with the T cell 
mitogen ConA (Sigma-Aldrich) at 5 μg/mL for 72 h in a 
humidified incubator 37 °C/5%  CO2. Cells were lysed by 
the addition of 1 mL of cell lysis buffer containing 0.1% 
v/v beta-mercaptoethanol. Total RNA was isolated using 
the RNeasy Mini Kit (Qiagen Inc., Manchester, UK) fol-
lowing the manufacturer’s instructions and cDNA was 
prepared by reverse transcription using  SuperScript® 
III Reverse Transcriptase (Invitrogen, Life Technolo-
gies, Paisley, UK) to serve as a template for the cloning 
of the IL-17A genes. The gene encoding bovine (bov) IL-
17A was amplified using specific primers encoding the 
full length sequences (for cattle bovIL17apEExsF2: CAA 
TAA GCT TCC ATG GCT TCT ATG AGA ACT TC 
and bovIL17apEExsR3: TCT GCC CGG GTC TTA AGC 
CAA ATG GCG) flanked by restriction enzymes sites 
HindIII and SmaI to facilitate sub-cloning into pEE14 
expression vector (Lonza, Slough, UK). At the start of the 
study no ovine IL-17A sequence was available so prim-
ers based on the bovine and caprine IL-17A sequences 
were used to clone the ovine gene (cahIL17apEExsF2: 
CAA TAA GCT TCC ATG GCG TCT ATG AGA 
ACT GC and ovIL17xsR2: TCT GCC CGG GTC TTA 
AGC CAC ATG GCG GAC) along with the restriction 
enzymes sites HindIII and SmaI to facilitate sub-cloning. 
BovIL-17A cDNA sequence derived from ConA-stim-
ulated PBMC was identical to the previously reported 
sequence (NM_001008412.2). The sequence of ovIL-17A 
derived in this study (LN835312, European Nucleotide 
Archive record) has a 100% identity with the ovIL-17A 
(XP_004018936.1) predicted from genomic DNA.
Conventional PCR protocols were undertaken to amplify 
the full length genes in a reaction containing: 1  µL of 
cDNA, 2.5 µL of 10× PCR buffer, 1.5 µL of  MgCl2, 0.5 µL 
10 mM dNTP, 0.1 µL of a mix of 10:1 Taq DNA polymer-
ase (5 U/mL) (Bioline, UK) and Pfu DNA polymerase (5 U/
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mL) (Promega, Madison, USA) and PCR water (Sigma-
Aldrich) to a volume of 25 μL. The PCR conditions for the 
amplification of both bovIL-17A and ovIL-17A consisted 
of an initial denaturation of 5 min at 95 °C, followed by 40 
cycles of 94 °C for 30 s, 60 °C for 30 s and 72 °C for 1 min. 
The PCR products were visualised on a 1% w/v agarose 
gel containing  SYBR® Safe DNA gel stain (Invitrogen, Life 
Technologies) using a UV light box and purified using a 
QIAquick Gel Extraction Kit (Qiagen Inc.) before ligation 
into pGEM-T Easy Cloning Vector (Promega).
After the transformation into XL1-Blue Competent 
Cells (Stratagene, Agilent Technologies Division, USA), 
the cells were grown on Luria–Bertani (LB) agar (Sigma-
Aldrich) supplemented with X-Gal and 10  mM IPTG 
overnight at 37  °C. White colonies were selected and 
grown overnight in 5  mL of LB medium with ampicil-
lin (100  µg/mL, Sigma-Aldrich), in a shaking incubator 
at 37  °C. Plasmid DNA from four independent colonies 
of bovIL-17A and ovIL-17A cDNAs was purified using 
a QIAprep Plasmid DNA Miniprep kit (Qiagen Inc.) 
following the manufacturer’s instructions and then 
sequenced to confirm the full length sequences using 
the T7 and SP6 sequencing primers (Eurofins Genomics, 
Ebersberg, Germany).
Bovine IL-17A and ovIL-17A cDNAs were compared 
for similarity using the Basic Local Alignment Search 
Tool (BLAST 2.5.1, [16, 17]). The predicted amino acid 
sequences were then analysed for the presence of a sig-
nal peptide using Signal 4.1 [18, 19]. The mature pro-
tein sequences were aligned with the corresponding 
sequences from a variety of vertebrates including repre-
sentative mammal, reptile and avian species using Clustal 
Omega [20, 21]). A matrix of pair-wise identity at the 
amino acid level was generated using Clustal 2.1. Evolu-
tionary sequence comparisons were undertaken using 13 
selected mammalian and other sequences with the mul-
tiple alignment generated using Clustal Omega. Prior to 
running the phylogenetic analysis the most appropriate 
amino acid substitution model was obtained by running 
the model selection module of TOPALi v2.5 [22]. The 
evolutionary relationships between the sequences were 
inferred using Mr. Bayes launched from TOPALI v2.5 
using the Jones–Taylor–Thornton plus gamma (JTT + G) 
model with two runs each of 1 250 000 generations with 
a burn in period of 20% and sampling frequency of 1000.
Expression vector construct production
The pEE14 vector was linearized and the confirmed 
bovIL-17A/ovIL-17A excised from pGEM-T Easy clones 
by double digestion using HindIII and SmaI at 37  °C 
for 3 h in 30 µL reactions. The digests were run in a 1% 
w/v agarose gel and bands excised and purified with a 
QIAquick Gel Extraction kit (Qiagen Inc.). The cDNA 
and linearized expression vector were then ligated in 1:3 
ratio of insert/vector using T4 DNA ligase (Promega) 
at 4  °C overnight. Ligated products were transformed 
into competent JM109 cells (Promega), and seeded into 
LB plates with ampicillin (100 µg/mL). Positive colonies 
were grown overnight in 5 mL of LB medium with ampi-
cillin in a shaking incubator at 37 °C. Plasmid DNA was 
purified as above and quantified using the Nanodrop 
spectrophotometer (NanoDrop Technologies, Thermo 
Fisher Scientific, MA, USA). Plasmid constructs were 
sequenced (Eurofins) to verify the integrity of the bovIL-
17A and ovIL-17A sequences.
Expression and quantification of recombinant bovine 
IL‑17A and ovine IL‑17A
Chinese Hamster Ovary (CHO) cells were used as the 
expression system for the cloned cytokine cDNAs. The 
CHO cells were maintained in Glasgow’s modified Dul-
becco’s Medium (GMEM, Sigma-Aldrich) supplemented 
with minimum essential medium non-specific amino 
acids (Gibco), 1  mM sodium pyruvate (Gibco), 410  μM 
glutamic acid (Sigma-Aldrich) with 450 μM l-asparagine 
(Sigma-Aldrich), 1.3  mM adenosine (Sigma-Aldrich), 
nucleosides (1.2  mM guanosine, 1.4  mM cytidine, 
1.4  mM uridine and 495  μM thymidine, all Sigma-
Aldrich), 10% heat-inactivated FBS (PAA Gold, Little 
Chalfont, UK) and 2  mM l-glutamine (Sigma-Aldrich), 
designated parent CHO medium [23]. CHO cells were 
subcultured twice weekly in 75  cm2 vent-capped tis-
sue culture flasks (Corning Costar, Scientific Labora-
tory Supplies Ltd) using 0.05% trypsin in versene/EDTA 
(Gibco and Sigma-Aldrich) for detachment. For trans-
fection, cells were seeded at 3  ×  105 cells/well in a six 
well plate (Nunc, Roskilde, Denmark) and incubated 
overnight at 37  °C/5%  CO2. Cells were then transfected 
with 3 µg of the plasmid vector pEE14 containing cDNA 
encoding either bovIL-17A or ovIL-17A cDNA using 
Lipofectamine 2000 (Invitrogen, Life Technologies Ltd) 
according to the manufacturer’s instructions. Transfected 
CHO cells were initially established in transfectant CHO 
medium comprising GMEM containing 7.5% dialysed 
(d) glutamine-free heat-inactivated FBS (Invitrogen) and 
25 µM methionine sulfoximine (MSX; Sigma-Aldrich).
Cells that survived the selective MSX inhibitor were 
subsequently amplified with increasing concentrations of 
MSX prior to cloning by limiting dilution to establish sta-
ble, cloned transfectant cell lines as previously described 
[24]. The supernatants from the IL-17A-transfected CHO 
cells were tested for the presence of rIL-17A using a com-
mercial bovine IL-17A ELISA with quantifiable reference 
standards (Kingfisher Biotech, Minneapolis, USA).
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Validation of transfected CHO cells expressing 
recombinant bovine IFN‑γ and ovine IFN‑γ
Existing transfected CHO cell lines expressing rbovIFN-γ 
and rovIFN-γ were used as positive controls for detection 
of intracellular IFN-γ. The CHO-expressed rbovIFN-γ 
and rovIFN-γ were evaluated by an in-house ELISA using 
the anti-bovine IFN-γ mab clones CC330 and CC302 
(Bio-Rad Laboratories, Oxford, UK) and commercial 
rbovIFN-γ (Pierce Endogen, Rockford, USA) as a quan-
tifiable reference standard. The biological activities of the 
rbovIFN-γ and rovIFN-γ were confirmed using a viral 
inhibition bioassay as described by Entrican et al. [25].
Bulk recombinant cytokine production and functional 
determination of recombinant bovine and ovine IL‑17A
For bulk recombinant cytokine production and matched 
negative-control supernatant, transfected and parent 
CHO cell lines were maintained routinely in 225  cm2 
flasks and sub-cultured twice weekly at a 1:10 ratio as pre-
viously described. Multiple flasks with sub-confluent cell 
monolayers from each cell line were grown prior to the 
preparation of serum-free conditioned medium as previ-
ously described [24], clarified by centrifugation at 1000 g 
at 4 °C for 10 min and stored at −80 °C until required. The 
CHO-expressed rbov and rovIL-17A were tested for their 
capacity to stimulate CXCL8 production in vitro using an 
Embryonic Bovine Lung cell line (EBL, kindly provided by 
Dr. Amin Tahoun and Professor David Gally, RI) and the 
ovine ST-6 cell line [26]. The EBL cells were subcultured 
in Dulbecco’s Modified Eagle Medium (DMEM, Invitro-
gen) containing 10% heat-inactivated FBS (PAA) defined 
as culture medium, using 75 cm2 vent-capped tissue cul-
ture flasks (Corning Costar, Scientific Laboratory Supplies 
Ltd). The ST-6 cells were similarly subcultured in Iscove’s 
Modified Eagle Medium (IMDM, Gibco, Life Tech-
nologies) containing 10% heat-inactivated FBS (PAA). 
Cells were adjusted to 1  ×  105/mL in culture medium 
and seeded in triplicate, at 500 µL/well in 48 well plates 
(Corning Costar, Scientific Laboratory Supplies Ltd) then 
cultured in a humidified incubator at 37 °C/5%  CO2 over-
night. The culture medium was then replaced with either 
serum-free conditioned CHO medium containing rbov 
or rovIL-17A adjusted to 100 ng/mL or serum-free con-
ditioned medium from untransfected CHO cells at an 
equivalent dilution. The resultant supernatants from the 
treated EBL and ST-6 cells were harvested 24 h later and 
stored at −20 °C until analysis for the presence of CXCL8 
by ELISA. This ELISA protocol has been described else-
where in detail [27] and is based on a murine anti-ovine 
CXCL8 mab 8M6 as a capture and rabbit anti-sheep 
CXCL8 polyclonal antibody for detection (Bio-Rad Labo-
ratories). This ELISA has also been shown to detect native 
bovine CXCL8 [28, 29].
Generation of native ovine IL‑17A
PBMC from six ewes (2–4 year old Greyface breed) were 
cultured at 2 × 106 cell/mL in 100 μL of IMDM supple-
mented with 10% heat-inactivated FBS, 50  μg/mL gen-
tamicin and 50  μM 2-mercaptoethanol in the presence 
or absence of 100  μL per well ConA (5  μg/mL) in a 96 
well U-bottom plate (Nunc) in a humidified incubator at 
37 °C/5%  CO2. Quadruplicate wells were set up for each 
treatment for the six animals. The culture supernatants 
from the technical replicates were harvested and pooled 
together after 96 h and stored at −20 °C prior to analysis 
by the commercial anti-bovine IL-17A ELISA (Kingfisher 
Biotech).
IL‑17A ELISpot
MultiScreen-IP Filter Plates (Merck Millipore, Hertford-
shire, UK) were activated by addition of 70% ethanol 
(Fisher Scientific, Loughborough, UK) for a maximum of 
2 min. Plates were washed five times with sterile  ddH2O 
and then incubated with 50  µL/well of 5  µg/mL rabbit 
polyclonal anti-bovine IL-17A antibody (product code 
PB0274B-100, Kingfisher Biotech) for 18 h at 4 °C. Simul-
taneously, PBMC from three cattle (8–12 month old Hol-
stein–Friesian) and three ewes (3  year old Texel-cross) 
were re-suspended in RPMI 1640 medium containing 
10% heat-inactivated FBS, 2 mM l-glutamine, 100 U/mL 
penicillin, 100  μg/mL streptomycin and 50  μM 2-mer-
captoethanol (RPMI culture medium) at a concentration 
of 2 × 106 cells/mL and stimulated with either 5 µg/mL 
ConA or culture medium alone for 18  h or for the last 
treatment culture medium for 12 h replaced with 50 ng/
mL phorbol 12-myristate 13-acetate (PMA, Sigma-
Aldrich) and 1 µg/mL ionomycin (ionomycin calcium salt 
from Streptomyces conglobatus, Sigma-Aldrich) for the 
final 6 h in a humidified incubator at 37 °C/5%  CO2. The 
plates were set up for three technical replicates for each 
treatment for each animal.
Following incubation with the coating antibody, the 
ELISpot filter plate was washed five times with ster-
ile PBS and subsequently incubated with 100  µL/well 
RPMI culture medium for 30  min at RT. Medium was 
removed and 2  ×  105 stimulated or unstimulated cells 
were added to each well, with each treatment in triplicate 
wells for each animal. The plate was incubated overnight 
at 37 °C/5%  CO2. The cells were removed from the ELIS-
pot plate wells and discarded. The plate was washed five 
times with PBS and 0.5  µg/mL biotinylated rabbit poly-
clonal anti-bovine IL-17A antibody (product code num-
ber PB0277B-50, Kingfisher Biotech) in PBS with 0.5% 
FBS was added to the wells and incubated for 2 h at RT. 
After a further five washes with PBS, wells were incu-
bated with a 1:1000 dilution of streptavidin conjugated 
to horse radish peroxidase (Sigma-Aldrich) in PBS with 
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0.5% FBS for 1 h at RT. After a final five washes with PBS, 
wells were incubated with SureBlue™ TMB Microwell 
Peroxidase Substrate (KPL, Maryland, USA) for 10 min at 
RT. Reactions were stopped by washing wells five times 
with  ddH2O and the plate was left to dry overnight prior 
to analysis using an AID EliSpot Reader HR (AID Auto-
immun Diagnostika GmbH, Straßberg, Germany) using 
AID EliSpot software version 4.0.
Evaluation of commercial antibodies for intracellular 
detection of IL‑17A
The cloned, transfected CHO cells served as source of 
constitutive IL-17A expression for evaluation of antibod-
ies and the CHO parent cells served as negative control 
cells. CHO cells were cultured as described above. For 
flow cytometry, cells were pelleted by centrifugation at 
626 g at 4  °C for 2 min and washed three times in cold 
PBS before being fixed in 0.5 mL of 1% paraformaldehyde 
(PFA, Sigma-Aldrich) at RT for 10 min. Cells were washed 
once more in cold PBS and adjusted to 1 × 107 cells/mL 
in PBS/0.05% (w/v) sodium azide (Sigma-Aldrich) and 
stored at 4 °C. The transfected CHO cells were prepared 
in advance and have been shown to be stable (without 
significant changes to detection of recombinant proteins 
by ICS or cell autofluorescence) when stored at +4 °C for 
several weeks (data not shown). Transfectant CHO cells 
stored in this way have been used to evaluate commercial 
antibodies for their capacity to bind recombinant ovine 
TNF-α [30] and recombinant ovine FoxP3 [31]. Prior to 
staining the cells underwent an overnight permeabilisa-
tion and block step. Cells were pelleted by centrifugation 
at 626 g for 2 min at 4 °C then resuspended to  107 cells/
mL in PBS containing 5% heat-inactivated FBS (PAA 
Gold), 0.05% (w/v)  NaN3 (Sigma-Aldrich), 0.2% (w/v) 
saponin (Sigma-Aldrich) (permeabilisation buffer) plus 
20% normal goat serum (Merck Millipore) (combined 
permeabilisation and blocking buffer) and maintained 
overnight at 4 °C consistent with our established protocol 
using transfectant CHO cells [30, 31].
The permeabilised and blocked CHO cells were then 
transferred to 96 well U-bottom plate (BD Falcon, Mas-
sachusetts, USA), 50  µL of cell suspension per well per 
labelling antibody. The cells were pelleted by centrifuga-
tion at 626 g for 2 min at 4 °C, aspirated in permeabilisa-
tion buffer and then 100 µL primary antibody or isotype/
equivalent matched control antibody or permeabilisation 
buffer alone was added for 30 min at 4 °C. A full detailed 
list of the commercial anti-IL-17A antibodies used in this 
study is provided in Table 1 and these were used accord-
ing to the manufacturer’s recommendations. A list of 
isotype-matched or equivalent polyclonal antibodies 
used as appropriate negative controls is shown in detail 
in Table  2. Cells were then washed by centrifugation at 
626  g for 2  min at 4  °C three times in permeabilisation 
buffer. The secondary antibody consisting of 100 μL per 
well goat anti-mouse-IgG-phycoerythrin (PE) conjugated 
(Invitrogen, USA) at 1 μg/mL in permeabilisation buffer 
for cells labelled with the primary mabs or 100  μL per 
well goat anti-rabbit IgG alexafluor 488 at 1  μg/mL for 
cells labelled with the primary pabs. Cells labelled using 
the RPE-conjugated anti-IL-17A mab were incubated 
in 100  μL per well in permeabilisation buffer alone for 
30 min at 4 °C. Cells were washed twice in permeabilisa-
tion buffer then finally washed in PBS prior to fixation in 
200 μL of 1% PFA and stored at 4 °C in the dark prior to 
acquisition. 
Cells were acquired for flow cytometric analyses using 
the MacsQuant flow cytometer (Miltenyi Biotech, Ger-
many) and analysed using the MacsQuantify Software 
v2.7. 20 000–50 000 events were collected and the sub-
sequent gating strategy shown in Additional file  2 fol-
lowed. Briefly, after removing artefacts with gating P1 
(Additional file 2A), P1/P2 was applied to the main popu-
lation to exclude debris (Additional file  2B) followed by 
P1/P2/P3 for doublet discrimination (Additional file 2C). 
The positive threshold setting in the phycoerythrin or 
alexafluor 488 channels P1/P2/P3/P4 were set using 
the isotype or equivalent control for each CHO cell line 
(Additional file  2D). Overlaying histogram plots of P1/
P2/P3 were used to compare anti-IL-17A antibodies 
with appropriate isotype or equivalent controls (Addi-
tional file 2E). Gated percentage numbers (P1/P2/P3/P4) 
and median fluorescence region values (P1/P2/P3) were 
measured for each antibody. Delta median fluorescence 
intensity (deltaMFI) was calculated by deducting the 
median mab isotype or pab control median fluorescence 
region value from the anti-IL-17A antibody median flu-
orescence region value. The summarised data are pre-
sented in Additional file 3.
IL‑17A and IFN‑γ expression by bovine and ovine T cell 
subsets
PBMC were prepared from whole blood from four cat-
tle (2 year old female Holstein–Friesian) and four sheep 
(3 year old Texel-cross), resuspended in RPMI-1640 cul-
ture medium, counted using Trypan Blue (ThermoFisher 
Scientific, Utah, USA) and adjusted to 1 × 107 cells/mL. 
2  ×  107 cells were stimulated with PMA (50  ng/mL), 
ionomycin (1 µg/mL), brefeldin A (10 µg/mL) diluted in 
RPMI culture medium for 4 h in sterile centrifuge tubes 
in a humidified incubator at 37 °C/5%  CO2.
Cells were pelleted by centrifugation at 258 g for 5 min 
at 4 °C and washed in PBS and samples reserved as con-
trols for the live/dead stain for flow cytometric analyses. 
1 × 107 cells were stained using the violet live/dead Fix-
able Dead Cell Stain Kit (Life Technologies) according to 
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the manufacturer’s protocol. Cells were fixed in 1% PFA 
for 10  min at RT. PBMC were permeabilised overnight 
as described above for the CHO cells (which also served 
as positive controls for the PBMC intracellular cytokine 
staining). 1 × 106 permeabilised PBMC were transferred 
into each well of a 96 well U-bottom plate (BD Falcon, 
Massachusetts, USA) then pelleted by centrifugation. 
A combined cell surface phenotyping and intracellular 
cytokine staining step was undertaken with directly-con-
jugated mabs and the appropriate isotype-matched and 
FMO controls in a volume of 100 μL per well for 30 min at 
RT (Table 3). Cells were pelleted, washed once in permea-
bilisation buffer and then once in PBS before final resus-
pension in 150 μL PBS. A minimum of 50 000 events were 
acquired using an LSRFortessa™ cell analyzer (Becton–
Dickinson) and analysed using FlowJo vX for Windows 7 
using the gating strategies shown in Additional file 4 (cat-
tle cells) and Additional file 5 (sheep cells).
Statistical analyses
The various datasets were analysed separately for statisti-
cal interpretation and the methods used will be outlined 
sequentially. The IL-17A bioassay datasets for the differ-
ential CXCL8 expression in technical replicates stimu-
lated with rbovIL-17A, rovIL-17A and CHO UTF control 
supernatant was statistically assessed using Kruskal–
Wallis tests for both bovine (EBL) and ovine (ST-6) cell 
lines. The native IL-17A expression of ovine PBMC from 
six animals in re-recall assays with ConA was analysed 
using the two-tailed Mann–Whitney test.
The ELISpot data were modelled by fitting a Poisson 
generalised linear mixed model (GLMM) by maximum 
Table 2 Isotype control mabs and control pab used in the evaluation of the commercial anti-IL-17A antibodies
The two mabs VPM21 and VPM22 (both MRI, Edinburgh, UK) and control pab (raised against bovine CD34; A & M University, Texas, USA) were derived from non-
commercial sources. The hybridoma cell lines were grown in-house to generate mabs that were then adjusted for concentration to match that of the anti-IL-17A mabs 
listed in Table 1. The antibodies were assigned a code letter in lower case that corresponds with the commercial antibodies listed in Table 1 (denoted by the equivalent 
uppercase letter) for the intracellular staining protocol followed in “Evaluation of commercial antibodies section”.
Control antibody used  
in the intracellular staining 
(CHO cells)
Clone Source Immunogen/host raised in Isotype Antibody 
conjugation, 
if present
a N/A Professor Waithaka Mwangi, A & 
M University, Texas, USA
Bovine CD34 construct/rabbit Rabbit IgG None
b, c and d VPM 21 Moredun Border disease virus/mouse Mouse IgG1 None
d VPM22 Moredun Border disease virus/mouse Mouse IgG2b None
Table 3 Commercial antibodies used in the detection of native intracellular IL-17A and IFN-γ by bovine and ovine T cell 
subsets
All details of antibody clones, product code, immunogen, host specificity and antibody conjugate are taken from datasheets provided by the commercial suppliers. 
The antibodies were used at the described dilutions for the cell phenotyping and intracellular cytokine staining described in “Expression of intracellular IL-17A and 
IFN-γ by bovine and ovine T cell subsets section”.
Antibody clone Commercial supplier 
and product code 
in brackets
Antibody isotype Target antigen Host specificity Antibody  
conjugation
Antibody dilution
CC8 Bio‑Rad Laboratories 
(MCA1653PE)
IgG2a CD4 Bovine Phycoerythrin 1:20
44.38 Bio‑Rad Laboratories 
(MCA2213PE)
IgG2a CD4 Ovine Phycoerythrin 1:20
CC58 Bio‑Rad Laboratories 
(MCA1654PE)
IgG1 CD8β Bovine Phycoerythrin 1:20
CC15 Bio‑Rad Laboratories 
(MCA838PE)
IgG2a WC‑1 Bovine Phycoerythrin 1:200
CC302 Bio‑Rad Laboratories 
(MCA1783A647)
IgG1 IFN‑γ Bovine Alexafluor‑647 1:200
eBio64DEC17 eBiosciences  
(17‑7179)
IgG1 IL‑17A Human APC 1:20
F8‑11‑13 Bio‑Rad Laboratories 
(MCA1209PE)
IgG1 Recognised rat 
cell surface 
marker
Rat Phycoerythrin 1:20
MRC OX‑34 Bio‑Rad Laboratories 
(MCA929PE)
IgG2a Rat cell surface 
marker
Rat Phycoerythrin 1:20
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likelihood to the IL-17A SFU/106 production, using log-
arithmic link function and Laplace approximations to 
calculate log-likelihoods. The model included treatment 
(ConA, medium and PMA/ionomycin), species (bovine, 
ovine) and their interaction as fixed effects and animal 
identification as a random effect in order to account for 
both within- and between-animal variability. An obser-
vation-level random effect term was specified to account 
for data over-dispersion. The statistical significance of 
the fixed effect terms was assessed using p values derived 
from type II Wald Chi square tests. Linear hypothesis 
tests were defined from the GLMM in order to conduct 
pair-wise comparisons of means between treatments and 
species. The associated p values were adjusted for false 
discovery rate (FDR) following Benjamini–Hochberg’s 
procedure [32].
A principal component analysis (PCA) was conducted 
to investigate the overall relationships between com-
mercial antibodies and specific binding capacity to rbov 
and rovIL-17A on the basis of the six metrics considered 
simultaneously. This statistical technique projects the 
information in multi-variable/-parameter datasets onto 
low dimensions, typically two dimensions, which is useful 
here to facilitate meaningful comparisons and clustering 
of the commercial antibodies by means of optimal linear 
combinations (principal components, PCs) of the origi-
nal metrics, that are represented visually in a biplot [33, 
34]. For example, Hemmink et  al. [35] have used PCA 
to analyse immunological datasets following an influ-
enza pathogenesis study in pigs showing the correlation 
of cytokine production, with viral titre over time. Our 
antibody screening results were displayed using a biplot 
based on the two first PCs (those accounting for the high-
est percentage of the total observed data variability) to 
facilitate discussion and ranking of the commercial anti-
bodies. Finally, in the bovine and ovine T cell subset phe-
notyping and combined intracellular staining datasets, 
the total percentage IL-17A and IFN-γ expression for cat-
tle and sheep PBMC were used to statistically assess the 
significance of differences in expression between species 
using two-tailed Mann–Whitney tests allowing for ties.
Statistical test significance was assessed at the 5% sig-
nificance level. The statistical analyses were conducted 
on the R system for statistical computing v3.2.
Results
Genetic relationships of mammalian IL‑17A sequences
BovIL-17A and ovIL-17A cDNA coding sequences were 
462 nucleotides in length and shared 97% identity. The 
predicted amino acid sequences including the signal 
peptide corresponded to 153 amino acids. According to 
SignalP 4.1, both bovIL-17A and ovIL-17A signal pep-
tides account for the first 23 amino acids and the mature 
peptides are 130 amino acids in length. The pair-wise 
identity matrix of the bovIL-17A and ovIL-17A with 
other published mature peptide sequences revealed 
identities of between 48.4 and 89.5% to the chicken and 
wild Bactrian camel respectively (Additional file 6). Fur-
ther analysis revealed over 99% identity between the 
bovine, ovine and caprine IL-17A amino acid sequences 
and a high degree of identity to human IL-17A (bovine 
and ovine 76.2%; caprine 75.8%). Evolutionary sequence 
comparisons using 13 selected mammalian and other 
sequences were inferred using Mr. Bayes launched 
from TOPALI v 2.5 using the Jones–Taylor–Thornton 
plus gamma (JTT  +  G) model, as shown in Figure  1. 
The sequences cluster to three groups with the caprine, 
bovine, ovine and swine sequences in one cluster. Given 
the pair-wise identities and the evolutionary relationships 
between the human and bovine and ovine sequences, 
we speculated that there would be a strong likelihood 
of mabs produced against human IL-17A binding to 
the bovine and ovine orthologues and that this could 
be definitively determined using the mammalian CHO 
expression system.
Expression, detection and biological function 
of recombinant ruminant IL‑17A
The Kingfisher Biotech bovine IL-17A VetSet is a pab-
based ELISA for detection of bovine IL-17A and based on 
the homology between the bovine and ovine orthologues, 
we predicted that it would detect both of the expressed 
recombinant proteins. Figure  2A shows titration curves 
for supernatant from transfected CHO cells expressing 
rbovIL-17A and rovIL-17A demonstrating the dynamic 
range that the rbov and rovIL-17A can be detected at 
using this commercial ELISA test. No signal was detected 
in supernatant from untransfected CHO cells (data not 
shown). The supernatant from the CHO line expressing 
rovIL-17A titrated over a wider range of concentrations 
than the rbovIL-17A-expressing CHO line. Quantifica-
tion of the supernatants using the Vetset kit recombinant 
bovine IL-17A standard revealed that rovIL-17A and 
rbovIL-17A supernatants had concentrations of 8809 and 
1660 ng/mL respectively.
We next established that the expressed recombinant 
proteins were functionally active. The supernatants were 
adjusted to 100  ng/mL for direct comparison of their 
ability to stimulate CXCL8 expression in a bovine (EBL) 
and ovine (ST-6) cell line (Figures 2B and C respectively). 
The magnitude of CXCL8 production by the two cell lines 
was notably different, with higher levels observed in the 
ovine ST-6 cell line compared to the bovine EBL cell line, 
irrespective of whether they were stimulated with rbo-
vIL-17A or rovIL-17A. One effect of rIL-17A is shown by 
the mean up-regulation of CXCL8 over the background 
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levels produced by EBL cells (p  =  0.027) or ST-6 cells 
(p =  0.027) exposed to supernatant from untransfected 
CHO cells. The rovIL-17A stimulated more CXCL8 
production than rbovIL-17A in both cell types. Hav-
ing shown that the bovine IL-17A Vetset ELISA detects 
rovIL-17A, consistent with publically-available cross-
species reactivity information, it was important to 
confirm that it could also detect and quantify native 
ovine IL-17A. Culture supernatants from ovine PBMC 
incubated for 96  h in the presence or absence of ConA 
were assessed for the presence of IL-17A by the Vetset 
ELISA. A low level of endogenous IL-17A was found in 
unstimulated cells, which was statistically significantly 
upregulated in response to ConA stimulation (p = 0.002, 
Figure 2D).
Enumeration of ruminant cells expressing IL‑17A 
by ELISpot
Quantification of cytokines in cell culture supernatants 
is one method for characterising the polarisation of cel-
lular immune responses and another is the enumeration 
of cells expressing individual cytokines. Given the ELISA 
results above, we decided to use the pabs from the Vetset 
ELISA to develop an IL-17A ELISpot to determine the 
frequency of IL-17A-producing cells in activated PBMC 
from cattle and sheep. Figures 3A and B show three tech-
nical replicates of PBMC from one cow and one sheep 
stimulated by ConA or PMA/ionomycin. Consistency 
of the technical replicates was clearly visible, as was the 
almost complete absence of IL-17A-secreting cells in 
the unstimulated controls. Note that these cells were 
Figure 1 Phylogenetic tree of mammalian IL-17A protein sequences. Evolutionary sequence comparisons were undertaken using 13 
selected mammalian and other IL‑17A sequences by initially conducting a multiple alignment using Clustal Omega (EMBL/EBI online, [21]). The 
evolutionary relationships between the sequences were inferred using Mr. Bayes launched from TOPALI v 2.5 using the Jones–Taylor–Thornton 
plus gamma (JTT + G) model with two runs each of 1 250 000 generations with a burn in period of 20% and sampling frequency of 1000. The 
horizontal lines are branches whose length represents the amount of genetic change over time. The scale bar shows the distance represented by 
0.1 expected substitutions per site. The robustness of the clustering of sequences are shown by the Bayesian Posterior Probabilities at the nodes. 
Accession numbers of the sequences used for the comparison are: Human NP_002181.1; House mouse NP_034682.1; Cow NP_001008412.1; 
Sheep XP_004018936.1; Goat NP_001272654.1; Horse NP_001137264.1; Pig NP_001005729.1; Dog NP_001159350.1; Domestic guinea pig 
NP_001265697.1; Koala AHZ08738.1; Chicken NP_989791.1; EGW10039.1 Chinese hamster and European rabbit AMQ91106.1. The phylogenetic tree 
was annotated using Dendroscope.
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Figure 2 Measurement and biological function of recombinant bovine and ovine IL-17A and detection of native ovine IL-17A by 
ELISA. A Detection of rbov and rovIL‑17A by ELISA. The supernatants from transfected CHO cells expressing rbovIL‑17A or rovIL‑17A, or control parent 
untransfected line (UTF) were serially diluted  (Log3 dilutions) and evaluated using the commercial bovIL‑17A ELISA. Data presented are optical density 
(OD) values from the Spectrophotometer at 450 nm. The X‑axis displays Dilution 1/X and the Y‑axis gives the OD value. Readings from UTF super‑
natant were below the limit of detection. B Functional activity of rbov and rovIL‑17A on bovine embryonic lung cells. Bovine embryonic lung (EBL) 
cells were stimulated with 100 ng/mL CHO‑expressed rbovIL‑17A or rovIL‑17A or UTF CHO negative control supernatant. Following 24 h incubation, 
culture supernatants were collected from triplicate cultures then tested for CXCL8 by ELISA. The X‑axis displays the bioassay treatments and the Y‑axis 
shows CXCL8 production in pg/mL. Data are the arithmetic mean of three technical replicates with error bars representing the standard error from 
one of three experiments. CXCL8 expression between treatments was statistically assessed using Kruskal–Wallis test. C Functional activity of rbov and 
rovIL‑17A on ovine ST‑6 cells. Ovine ST‑6 cells were stimulated with 100 ng/mL CHO‑expressed rbovIL‑17A or rovIL‑17A or UTF CHO supernatant. Fol‑
lowing 24 h incubation and culture supernatants collected, tested and analysed as described in Figure 2B. CXCL8 expression between treatments was 
statistically assessed using Kruskal–Wallis test. D Detection of native ovIL‑17A by ELISA. Ovine PBMC were cultured at 2 × 106 cells/mL with or without 
5 μg/mL ConA. Culture supernatants were analysed for IL‑17A using the bovIL‑17A ELISA. Data represent the arithmetic mean of PBMC from six ewes 
and error bars represent standard error. Data were analysed statistically for significance using the two‑tailed Mann–Whitney test.
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only cultured for 18 h as opposed to 96 h for the ELISA 
analyses where a positive signal was detected in superna-
tants of unstimulated cells. Figure 3C shows the average 
number of spots from activated PBMC from three cattle 
and three sheep. The average number of spots in cattle 
and sheep PBMC was similar when activated by PMA/
ionomycin [1789.74 Spot Forming Units (SFU) ± 314.42 
vs 1731.72 SFU ± 304.29, p = 0.895], whereas the mean 
frequency of IL-17A-producing cells was statistically 
significantly lower in cattle PBMC compared to sheep 
PBMC when activated with ConA (546.95 SFU ±  96.32 
vs 1130.53 SFU ± 198.76, p = 0.004).
Identification of antibodies that detect recombinant 
intracellular bovine and ovine IL‑17A by flow cytometry
While the ELISpot provides the capability to enumer-
ate the frequency of IL-17A-producing cells and esti-
mates cell-level production determined by spot-size, 
flow cytometry can provide additional information on 
the relative levels of IL-17A produced per cell and also 
identify the phenotype of the producing cell. We used 
the transfected CHO cells as stable expressers of IL-17A 
to screen a panel of available mabs and pabs (Table  1) 
for their ability to detect intracellular bovine and ovine 
IL-17A. Although the rbovIL-17A and rovIL-17A trans-
fectant CHO cells are derived from the same parent 
untransfected CHO cells, all three cell lines have different 
size and granularity properties. To define specific cross-
reactive staining of the antibody panel, it was necessary 
to draw multiple parameter comparisons by overlaying 
histograms of isotype-matched or appropriate pab con-
trols and calculating the percentages of cells in the gated 
positive regions from P1/P2/P3/P4 and the deltaMFIs 
of the entire cell population using the median fluores-
cence region values within the P1/P2/P3 region relative 
to appropriate control antibodies (Additional file  2). A 
Figure 3 Detection of single-cell expression of ruminant IL-17A by ELISpot. Plates and PBMC were prepared and cultured as described in 
“IL‑17A ELISpot section”. ELISpot images shown are representative of PBMC from one of three cattle (A) and one of three sheep (B) activated with 
ConA and PMA/ionomycin. The average number of spot‑forming units (SFU) with standard errors are shown for  106 PBMC from all three cattle 
(grey bars) and sheep (black bars), stimulated under the different conditions (C). Data were modelled by fitting a Poisson generalised linear mixed 
model (GLMM) by maximum likelihood to the IL‑17A SFU/106 values, using logarithmic link function and Laplace approximations to calculate 
log‑likelihoods. The model included treatment (medium control, ConA and PMA/ionomycin), species (bovine, ovine) and their interaction as fixed 
effects and animal identification as a random effect in order to account for both within‑ and between‑animal variability. An observation‑level 
random effect term was specified to account for data over‑dispersion. The statistical significance of the fixed effect terms was assessed using p 
values derived from type II Wald Chi square tests. Linear hypothesis tests were defined from the GLMM in order to conduct pair‑wise comparisons 
of means between treatments and species. The associated p values were adjusted for false discovery rate (FDR) following Benjamini–Hochberg’s 
procedure.
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summary of the numerical percentage positivity and 
deltaMFIs for all of the commercial IL-17A antibodies 
screened against the UTF CHO, rbov IL-17A CHO and 
rov IL-17A CHO cells can be found in Additional file 3 
which provides six measures to evaluate specific capac-
ity to bind the IL-17A cytokine through intracellular 
staining.
As we had previously confirmed that the Vetset pabs 
detected both recombinant and native bovine and 
ovine IL-17A by ELISA and ELISpot, we first evalu-
ated the unconjugated pab for intracellular staining of 
the CHO cells using an anti-rabbit second-stage con-
jugate. Although positive staining was observed in the 
transfected CHO cells, there was also a considerable 
background signal with the untransfected CHO cells, 
possibly reflective of the use of a pab control antibody 
(Figure 4A). We then screened the panel of seven mabs 
(listed in Table  1) against the CHO transfectants. Only 
two (eBio64DEC17 and MT504) of the seven mabs tested 
were found to specifically cross-react with rbovIL-17A 
and rovIL-17A in the CHO cells (Figures 4B and C). Both 
of these mabs were raised against recombinant human 
IL-17A. Clone eBio64DEC17 clone gave a higher per-
centage binding in the positive region and deltaMFI val-
ues (38.7%+ve/deltaMFI of 1.03 to the bovIL-17A CHO 
cells and 92.9%+ve/deltaMFI of 6.07 to the ovIL-17A 
CHO cells respectively) relative to the isotype-matched 
mab control (displayed in Figure 4B and metrics shown 
Additional file 3). The respective values for MT504 were 
61.7%+ve/deltaMFI 1.27 and 96.0%+ve/deltaMFI 6.72 
(displayed in Figure  4C and metrics shown in Addi-
tional file  3). Note the absence of non-specific staining 
with these mabs on the untransfected control (UTF) 
CHO cells (displayed in Figures  4B  and C). Mab 41809 
has a negligible proportion of cells in the positive region 
whereas mab 41802 gave a high degree of non-specific 
staining using the UTF CHO cells (deltaMFI of 2.45 and 
94.1% of cells in the positive region) compared to the 
combined isotype controls (Figure 4D). Both mabs have 
high percentage positivity for bovIL-17A and ovIL-17A 
based on the region boundary (displayed in Figure  4D 
and metrics shown Additional file  3), but the very low 
deltaMFIs (41809: 0.14 (rbov) and 1.12 (rov) and 41802: 
0.11 (rbov) and 0.2 (rov) respectively) indicating poor 
specificity with bovIL-17A and ovIL-17A.
The six metrics used to assess antibody binding to 
rbov and rovIL-17A (numerical percentage in posi-
tive upper region and deltaMFIs for the three CHO 
cell lines) were represented along with the antibodies 
in a PCA biplot providing an additional objective way 
to rank them displayed in Additional file  7. Data for 
the unconjugated pab were excluded as it was the only 
non-mab and appeared to be distorting the overall rep-
resentation of the other antibodies when included in the 
PCA analyses. The biplot planar representation based 
on the two first PCs (on the horizontal, PC1, and verti-
cal axes, PC2, respectively) explained 87.37% of the vari-
ability of the original data set. The distances between 
the antibodies (represented by symbol points) spatially 
reflect their similarity in regards to the original six met-
rics (represented by axes, with arrows indicating direc-
tions of higher values). The mabs eBio64DEC17 and 
MT504 associate together linking to the highest values 
of the rbovIL-17A and rovIL-17A deltaMFI variables. 
The mabs MT44.6, MT241 and MT2270 overlap linking 
to the lowest values in the rbovIL-17A and rovIL-17A 
MFI variables. Mab 41809 has a negligible proportion 
of cells in the positive region whereas Mab 41802 gave a 
high degree of non-specific staining using the UTF CHO 
cells (deltaMFI of 2.45 and 94.1% of cells in the posi-
tive region) compared to the combined isotype controls 
(Figure 4D). The angles between axes are representative 
of the types of correlation between the corresponding 
metrics. Hence, the small angles observed between the 
axes for bovIL-17A %, CHO UTF deltaMFI, CHO UTF 
% and ovIL-17A % on the one hand, and those for ovIL-
17A deltaMFI and bovIL-17A deltaMFI on the other 
hand, are indicative of high correlations within each of 
these two sets of metrics. The angle of approximately 90° 
between these two sets of metrics reflects negligible cor-
relation between them. Together our dataset suggests 
that bovIL-17A and ovIL-17A deltaMFI metrics provide 
a more reliable measure of specific IL-17A binding than 
%# bovIL-17A and %# ovIL-17A respectively.
Of all of the antibodies listed in Table  1, only the 
MT504 mab clone is available in a form that is compat-
ible with use in tissue culture and not stored in a buffer 
containing sodium azide. As this mab gave positive stain-
ing on the transfected CHO cells by flow cytometry, 
we assessed its potential to neutralise the bioactivity of 
rbovIL-17A and rovIL-17A. 1 μg/mL of mab MT504 was 
mixed with 50 ng/mL of rbovIL-17A and rovIL-17A for 
2 h at 37 ºC then tested for induction of CXCL8 expres-
sion in ovine ST-6 cells as described previously in “Bulk 
recombinant cytokine production and functional deter-
mination of recombinant bovine and ovine IL-17A  sec-
tion” and shown in Figure  2C. The pre-mixing of the 
mab with recombinant IL-17A resulted in 65.3 and 62.8% 
decreases in CXCL8 release for rbovIL-17A and rovIL-
17A respectively indicating the ability of mab MT504 
to neutralise the biological activity of ruminant IL-17A 
(Additional file 8).
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Figure 4 Evaluation of commercial antibodies for the intracellular detection of recombinant bovine and ovine IL-17A. The eight 
commercial antibodies listed in Table 1 were tested against fixed, permeabilised untransfected (UTF) CHO cells and CHO cells transfected with 
cDNA encoding bovIL‑17A or ovIL‑17A for their capacity to detect intracellular recombinant IL‑17A by flow cytometry. Results are shown for one 
polyclonal antibody (pab) produced against bovIL‑17A (A) and seven monoclonal antibodies (mabs) produced against human or mouse IL‑17A 
(B–D). Profiles of the relevant control antibodies listed in Table 2 are included in the overlapping histograms. Events were acquired on the Macs‑
Quant according to the gating strategy described previously (in brief ) and shown in Additional file 2. Line colours representing different antibody 
treatments are given in parentheses: A Primary rabbit anti‑bovine IL‑17A pab PB0274B‑100 at 1 μg/mL (A.1, red) or negative control primary anti‑
bovine CD34 pab (in‑house) at an estimated 1 μg/mL equivalent (a, black) then detected with a secondary goat anti‑rabbit alexafluor 488 at 1 μg/
mL; B Directly conjugated mouse anti‑human IL‑17A eBio64DEC17‑phycoerythrin (PE) mab (IgG1) at 2.5 μg/mL (B.1, red) and control IgG1 VPM21 
mab (in‑house) at an estimated 2.5 μg/mL equivalent (b, black) and detected with goat anti‑mouse PE at 1 μg/mL; C Primary mouse anti‑human 
IL‑17A mabs MT44.6 (C.1, blue), MT241 (C.2, green), MT2770 (C.3, brown) and MT504 (C.4, red) [all IgG1] at 0.5 μg/mL and control IgG1 VPM21 mab 
(in‑house) at an estimated 0.5 μg/mL equivalent (black), all detected with goat anti‑mouse PE at 1 μg/mL; D Primary mouse anti‑human IL‑17A 
mabs #41809 (D.1, red) (IgG2b) and #41802 (D.2, blue) (IgG1) at 2.5 μg/mL and a mixture of control mabs VPM21 (IgG1) and VPM22 (IgG2b) at an 
estimated 2.5 μg/mL equivalent (d, black), all detected with goat anti‑mouse PE at 1 μg/mL.
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Expression of intracellular IL‑17A and IFN‑γ by bovine 
and ovine T cell subsets
PBMC from cattle and sheep were activated with PMA/
ionomycin and the expression of intracellular cytokines by 
different T cells subsets was measured by double staining. 
Representative plots of the double staining of activated 
PBMC (one of four biological replicates) showed that 
CD4+ve, CD8β+ve (dim) and WC-1+ve cells from cattle 
whereas CD4+ve and WC-1+ve cells from sheep are capa-
ble of expressing intracellular IL-17A (Figures  5  and 6). 
Compared to the activated bovine PBMC, there are insuf-
ficient events to confirm the presence of CD8+ve(dim) 
cells expressing IL-17A in activated ovine PBMC. The pro-
portions of cells expressing IL-17A are lower than those 
expressing IFN-γ in both cattle (Figure 5) and sheep (Fig-
ure 6), with the exception of the WC-1+ve cells in cattle 
which were proportionately greater for IL-17A. The bovine 
PBMC occupying the WC-1+ve IFN-γ+ve region in Fig-
ure 5F are mostly artefactual and non-specific (rectangu-
lar population crossing the region boundary for WC-1+ve 
region). However, under these stimulatory conditions, cat-
tle PBMC proportionately expressed more IL-17A com-
pared to sheep PBMC (Figure 7A; p = 0.020) whereas for 
IFN-γ the converse was true (Figure 7B; p = 0.021).  
Discussion
Since the discovery of two types of murine T cell clones 
with distinct cytokine expression [36], our knowledge of 
the cytokine profiles and function of the extended fam-
ily of Th subsets has greatly expanded. In the process 
of gaining a deeper understanding of how the different 
CD4+ve Th subsets are induced to protect against dif-
ferent infections, it has become clear that they are no 
longer considered to be mutually-exclusive or irreversibly 
committed, but demonstrate a degree of plasticity and 
cross-regulation (reviewed by Zhu et  al. [3]). Single-cell 
technologies are providing further insights into T cell 
biology and regulation of immune responses [37] which 
underpins novel strategic approaches to disease control 
and vaccine design.
Of the CD4+ve Th subsets described in mice, there 
appears to be a particular plasticity between Th-17 and 
Th-1 cells. In a model of diabetes purified Th-17 cells 
adoptively transferred into recipient mice have been 
shown to convert to Th-1-type cells secreting IFN-γ 
[38]. This close relationship of Th-1-type and Th-17-type 
responses and the cytokines that contribute to their dif-
ferentiation, namely IL-12 and IL-23, that share the com-
mon p40 subunit, underlines the importance of being 
able to identify T cell cytokine profiles in target species. 
While the capability to study IFN-γ-related responses in 
farmed ruminants is advanced, there are relatively few 
reports describing the cellular expression and function of 
the IL-17 cytokine family.
Bougarn et al. [12] described the cloning of bovine IL-
17A and IL-17F and the expression of biologically-active 
recombinant proteins in insect cells that could induce 
expression of a range of cytokines and chemokines 
(including CXCL8) in primary bovine mammary epithe-
lial cells. We have taken the approach of comparing cat-
tle and sheep by cloning and stably expressing bovine and 
ovine IL-17A in CHO cells. The rbovIL-17A and rovIL-
17A were shown to be functionally active as they stimu-
lated CXCL8 expression in fibroblasts and epithelial cells. 
The sequence identity of the mature bovine IL-17A pro-
tein with the ovine orthologue IL-17A is 100% which is 
reflected by their reciprocal species cross-reactivity (Fig-
ures 2B and C).
There have been several publications reporting the 
expression of mRNA encoding bovine IL-17A (and other 
IL-17 family members) as measured by RT-PCR [9, 39, 
40]. There have also been publications reporting the 
quantification of IL-17A protein in cattle using the anti-
bovIL-17A ELISA Vetset marketed by Kingfisher Biotech 
[10, 11, 39, 41, 42]. A principal objective of our study was 
to use the transfected CHO cells and their expressed 
recombinant proteins as defined standards to identify 
cross-reactive antibodies and to further refine methods to 
detect bovIL-17A and ovIL-17A. We have demonstrated 
for the first time the ability of the Kingfisher bovIL-17A 
Vetset to detect and quantify native ovIL-17A in the cul-
ture supernatants of mitogen-activated sheep PBMC (Fig-
ure  2D). The bovIL-17A Vetset ELISA antibodies have 
been used in an ELISpot to identify IL-17A-secreting 
CD4+ve and gamma-delta (γδ)T cells in cattle [43]. We 
have added to that capability by using these antibodies in 
an ELISpot to quantify the frequency of both bovIL-17A- 
and ovIL-17A-secreting cells in populations of activated 
PBMC (Figure  3). Our results show that PMA/ionomy-
cin is a more potent stimulator of IL-17A in PBMC than 
ConA which is consistent with observations in human 
PBMC [44]. ConA induced a higher mean frequency of 
IL-17A-secreting cells from sheep PBMC than cattle, the 
reasons for which are unclear (Figure 3) but may include 
variability associated with age, breed and environment.
As described above, the ability to identify and quantify 
cytokine expression at the single-cell level by flow cytom-
etry is invaluable for characterising cellular immune 
responses and informs on vaccine delivery strategies. 
The transfected CHO cells revealed that the bovIL-17A 
Vetset antibodies that were utilised successfully in ELISA 
and ELISpot were not optimal for intracellular IL-17A 
flow cytometric staining due to non-specific binding to 
untransfected cells (Figure  4A). We therefore focussed 
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on screening a panel of seven anti-human or anti-mouse 
IL-17A mabs for ability to detect cattle and sheep IL-
17A intracellularly. One of these mabs (eBio64DEC17) 
has been reported to detect intracellular IL-17A in sheep 
lymphocytes [45] and cattle, sheep and goat PBMC [46]. 
In these previous studies the cross-reactivity is implied as 
there was no validation against a specific control where 
IL-17A was known to be expressed. We have shown in a 
number of studies that stably transfected CHO cells con-
stitutively express high levels of recombinant cytokines 
[30] and the transcription factor FoxP3 [31]. We have 
previously shown that brefeldin A increases intracellular 
accumulation of cytokine in the transfectants but does 
alter not the percentage positivity of the cells [47]. The 
intracellular cytokine staining of activated lymphocytes 
tends to be lower than the transfectants. Consequently, 
amplifying the signal even further in the CHO cells would 
not help select antibodies for native staining or give a 
better indication of their working dilutions for activated 
lymphocytes. In the present study, we found that eBio-
64DEC17 and another anti-human IL-17A mab (MT504) 
gave high deltaMFI values for bovIL-17A and ovIL-17A 
(Figures  4B  and C), findings that were objectively con-
firmed using the PCA biplot analysis (Additional file 7). 
We demonstrate that deltaMFIs and to a lesser extent 
percentage of cells (in relation to appropriate control 
antibodies) can be used to objectively rank antibodies 
for their capacity to bind. MT504 clone is available in a 
tissue culture compatible format and was capable of neu-
tralising rbovIL-17A and rovIL-17A function in  vitro 
(Additional file 8). This mab adds to the panel of antibod-
ies available to neutralise ruminant cytokine function 
which includes mabs 3C2 for ovine GMCSF [24], CC320 
for bovine IL-10 [48] and CC326 for bovine IL-12 [49].
Figure 5 Intracellular expression of IL-17A and IFN-γ by activated bovine T cell subsets. PBMC from four cattle were stimulated with 
phorbol 12‑myristate 13 acetate, ionomycin and brefeldin A in RPMI culture medium for 4 h. Cells were harvested and stained for viability and with 
mabs specific for cell‑surface phenotypic markers and intracellular cytokines as described in Table 3 and “Expression of intracellular IL‑17A and 
IFN‑γ by bovine and ovine T cell subsets section”. Cells were stained for CD4 with mab CC8‑PE at 1:20 dilution (A, D), for CD8β with mab CC58‑PE 
at 1:20 dilution (B, D) and for WC‑1 (γδ T cells) with mab CC15‑PE at 1:200 (C, E). Intracellular cytokine staining for IL‑17A was conducted using mab 
eBioDEC17‑APC at a 1:20 dilution (A–C) and for IFN‑γ using mab CC302‑Alexafluor 647 at a 1:200 dilution (D–F). Data are shown for PBMC from one 
representative animal of four.
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We compared intracellular staining for IL-17A using 
mab eBio64DEC17 with intracellular staining for IFN-γ 
in combination with cell-surface phenotyping to com-
pare cytokine expression in activated cattle and sheep 
PBMC. Since the cytokines and the receptors involved in 
the production of IL-17A and IFN-γ share common com-
ponents, it is important to know if distinctive T cell sub-
sets expressing these cytokines exist in ruminants as they 
appear to in other mammalian species. We found that 
the major T cell subsets (CD4+ve and WC-1+ve) can 
express IL-17A (Figures 5 and 6), consistent with reports 
in humans [50] and mice [51, 52]. We found CD8+ve 
IL-17A for cattle PBMC but had insufficient cells to con-
firm their presence in PMA/ionomycin-stimulated ovine 
PBMC. Further evidence ideally in an antigen-driven 
setting is required to determine the existence of this cell 
population in sheep. There was a higher mean proportion 
of activated cattle PBMC expressing IL-17A than sheep 
PBMC, the converse being true for IFN-γ (Figure 7). The 
reason for this difference is unclear. The expression of 
bovine and ovine IL-17A by CD4+ve and WC-1+ve/γδT 
cell subsets is consistent with other studies using a com-
bination of flow cytometry and ELISpot [43, 45]. Only 
0.2% of total WC-1+ve/γδT cells from activated ovine 
PBMC expressed IL-17A in our study, whereas around 
6% of total WC-1+ve/γδT cells were constitutively IL-
17A+ve from skin-draining lymph. This difference is 
possibly reflective of the altered capacity for surveillance 
and mobilisation at the skin to cutaneous infection [45]. 
Our data show that activated bovine CD8+ve(dim) T 
cells also have the capacity to produce intracellular IL-
17A, the first report of this phenomenon in ruminants, 
but consistent with reports of human CD8+ve T cells 
(reviewed by Srenathan et al. [51]).
IL-17A has an important role particularly at mucosal 
barriers such as the skin, lung and intestinal tract where 
Figure 6 Intracellular expression of IL-17A and IFN-γ by activated ovine T cell subsets. PBMC from four sheep were stimulated with phor‑
bol 12‑myristate 13 acetate, ionomycin and brefeldin A in RPMI culture medium for 4 h. Cells were harvested and stained for viability and with mabs 
specific for cell‑surface phenotypic markers and intracellular cytokines as described in Table 3 and “Expression of intracellular IL‑17A and IFN‑γ by 
bovine and ovine T cell subsets section”. Cells were then stained for CD4 with mab 44.38‑PE at 1:20 dilution (A, D), CD8β with mab CC58‑PE at 1:20 
dilution (B, D) and WC‑1 (γδ) with mab CC15‑PE at 1:200 (C, E). Intracellular cytokine staining for IL‑17A was conducted using mab eBio64DEC17‑
APC a 1:20 dilution (A–C) and for IFN‑γ using mab CC302‑alexafluor 647 at a 1:200 dilution (D–F). Data shown is for one representative animal out of 
four.
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its production can be crucial to the control or exacer-
bation of inflammation in humans or mice [53]. The 
new tools and assays developed in this study will enable 
greater investigation of mucosal compartments in rumi-
nants to improve understanding of host response to 
infection in situ. The capability to measure both IL-17A 
and IFN-γ by intracellular staining will help determine 
if the Th-cell plasticity observed in Th-17 cells convert-
ing to a Th-1 IFN-γ-secreting phenotype in mice [38] can 
occur in ruminant species.
The validation and quality assurance of antibodies is 
currently a topic of great interest with several opinion 
articles discussing their impact on scientific advance-
ment including inability to reproduce published data, the 
duplication of effort for testing reagents in specific assays 
and time lost due to use of unreliable reagents [54–56]. 
This is especially important in veterinary immunology 
as investment in immunological reagent development is 
relatively low [57].
In this study we have developed the capacity to meas-
ure native ovine IL-17A in liquid phase by ELISA and 
identify positive secreting cells by ELISpot using existing 
pabs from the commercial bovine ELISA. We have used 
molecular cloning techniques to generate stable mamma-
lian CHO cells expressing recombinant IL-17A (consti-
tutive positive and UTF negative controls) for screening 
a panel of commercial anti-IL-17A antibodies. Using 
PCA on six parameters we have represented the spe-
cies cross-reactivity data identifying two suitable mabs 
for intracellular staining for sheep and cattle cells. We 
are able to identify CD4, CD8β and WC-1+ γδ T cells 
from activated bovine and ovine PBMC and block IL-17A 
activity. We took the approach of screening existing anti-
bodies for detection of bovine and ovine IL-17A rather 
than embark on the production of new pabs or mabs 
against our recombinant proteins. This approach has the 
ethical advantage of avoiding immunisation schedules 
and therefore animal usage. There is always the possibil-
ity that higher affinity antibodies could be made against 
the homologous cytokine for each species by immunisa-
tion, but in balance we have shown that mabs produced 
against human cytokines can cross-react with ruminant 
cytokines. Confidence in the specific labelling is provided 
with the use of sufficiently robust controls. In summary, 
the tools we describe here for IL-17A will improve our 
ability to characterise inflammatory immune responses 
in ruminants and our understanding of host-pathogen 
interactions to inform on rational vaccine development.
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Figure 7 Relative intracellular expression of IL-17A and IFN-γ 
by activated bovine and ovine PBMC. The data sets described in 
“Expression of intracellular IL‑17A and IFN‑γ by bovine and ovine T cell 
subsets section” and presented in Figures 5 and 6 are summarised to 
compare overall intracellular expression of IL‑17A (A) and IFN‑γ (B) by 
PMA/ionomycin‑stimulated bovine and ovine PBMC. Each bar repre‑
sents the arithmetic mean of four cattle or four sheep and the error 
bars represent the standard error. The data for total percentage IFN‑γ 
and IL‑17A expression between species were assessed statistically 
using two‑tailed Mann–Whitney tests allowing for ties. Additional files
Additional file 1. Bovine, ovine and caprine IL-17 family sequences 
in publically accessible databases. A list of the known IL‑17 family 
orthologue sequences is shown where all sequences are full unless 
otherwise stated. The source of the sequence is stated either from 
mRNA/cDNA or predicted from genome annotation and the National 
Center for Biotechnology Information (NCBI, accessed 04/03/2017) 
accession numbers are as stated below: Cow (Bos taurus): IL‑17‑A 
EU682381.1; IL‑17B NM_001192045.1; IL‑17C XM_010826654.2; IL‑17D 
transcript variant X1 XM_015465706.1; IL‑17E/IL‑25 XM_015464998.1 
and IL‑17F NM_001192082.1. Sheep (Ovis aries): IL‑17A XM_004018887.3; 
IL‑17B transcript variant X1 XM_012178770.2; IL‑17C transcript 
variant X1 XM_012189660.2; IL‑17D no accession record; IL‑17E/IL‑25 
NM_001195219.1 and IL‑17F XM_004018888.3. Goat (Capra hircus): IL‑17A 
GU269912.1; IL‑17B XM_005683151.3; IL‑17C XM_005683151.3; IL‑17D 
transcript variant X1 XM_018056543.1; IL‑17E/IL‑25 XM_018054603.1 and 
IL‑17F XM_005696412.2.
Additional file 2. Gating strategy used for the evaluation of com-
mercial antibodies to bind intracellular recombinant bovine and 
ovine IL-17A in fixed cells. Cells were acquired for flow cytometric 
analyses using the MacsQuant flow cytometer and analysed using the 
MacsQuantify Software. 20 000–50 000 events were collected and the 
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following gating strategy was followed. Cells in the plot of Forward 
Scatter‑Area (FSC‑A) against the high dynamic range over time (HDR‑T) 
are gated in P1 to exclude any non‑specific artefacts (A). The P1/P2 gate 
represents Side Scatter‑Area (SSC‑A) plotted against FSC‑A set to identify 
the main cell population and exclude debris (B). Single cells were gated 
(P1/P2/P3) using FSC‑Height (H) vs FSC‑A for doublet discrimination 
(C). Finally, the cells of interest were identified in the phycoerythrin or 
alexafluor 488 channel vs SSC‑A (P1/P2/P3/P4) where regions were set 
using the isotype or equivalent control for each CHO cell line to establish 
threshold gates (D). Overlaying histogram plots of phycoerythrin or 
alexafluor 488 using (P1/P2/P3) gating strategy selecting for all cells in the 
region (equivalent to cells above and below region boundary in plot D) 
(E) were used to compare anti‑IL‑17A antibodies with appropriate isotype 
or equivalent controls presented in Figure 4. Gated percentage numbers 
above the region boundary (P1/P2/P3/P4) and median fluorescence 
region values (P1/P2/P3) were measured for each antibody in the relevant 
fluorochrome channel phycoerythrin or alexafluor 488. Delta median 
fluorescence intensity (deltaMFI) was calculated by deducting the median 
fluorescence region value for mab isotype control or pab control from the 
anti‑IL‑17A antibody value for the appropriate fluorochrome channel. The 
summarised data are presented in Additional file 3.
Additional file 3. Summary of commercial IL-17A antibody 
evaluation for capacity to bind intracellular recombinant bovine 
and ovine IL-17A in fixed Chinese Hamster Ovary cells. Control 
antibodies are listed in lower case, the anti‑IL‑17A antibodies are listed 
in upper case. Using the gating strategy described in brief in evaluation 
of commercial antibodies subsection (displayed in Additional file 2) the 
following data are shown: P1/P2/P3/P4 percentage of cells above the 
region boundary line of phycoerythrin or alexafluor 488 channels vs Side 
Scatter‑Area (denoted #%); P1/P2/P3 median fluorescence region value 
(phycoerythrin or alexafluor 488 channels); and delta median fluorescence 
intensity (deltaMFI) calculated by taking the median fluorescence region 
values (phycoerythrin or alexafluor 488 channels) for the commercial 
IL‑17A antibody and deducting the median fluorescence region value of 
the appropriate isotype or equivalent control antibody in the same fluo‑
rochrome channel) for the CHO UTF, bovIL‑17A and ovIL‑17A transfected, 
fixed CHO cells.
Additional file 4. Gating strategy for the identification of activated 
bovine T cell subsets expressing intracellular IL-17A and IFN-γ. 
Activated bovine PBMC were stained for viability, cell surface markers and 
intracellular cytokines according to the protocol outlined in “Expression of 
intracellular IL‑17A and IFN‑γ by bovine and ovine T cell subsets section” 
using antibodies listed in Table 3 and acquired using an LSRFortessa™ 
cell analyzer (Becton–Dickinson). Cells were gated to eliminate dead cells 
using the Vioblue Live/Dead® Fixable Dead Cell Stain Kit, Side Scatter 
Height (SSC‑H) vs Vioblue channel (A) and to include only single cells 
Forward Scatter Height (FSC‑H) vs FSC‑Area (FSC‑A) (B). Gated single 
cells used for subsequent two‑colour cell phenotyping and intracellular 
cytokine staining (C). Quadrant region boundaries were set based on 
isotype‑matched directly conjugated antibody controls (FITC vs APC/
Alexafluor 647 channels, D) and (Phycoerythrin vs APC/Alexafluor 647 
channels, E) and fluorescence minus one (FMO) controls for each cell 
marker (WC‑1, F; CD4, G; CD8β, H) and for each cytokine IL‑17A, I‑J and 
IFN‑γ, K‑L). Data are shown for one representative animal of four.
Additional file 5. Gating strategy for the identification of activated 
ovine T cell subsets expressing intracellular IL-17A and IFN-γ. 
Activated ovine PBMC were stained for viability, cell surface markers and 
intracellular cytokines according to the protocol outlined in “Expression of 
intracellular IL‑17A and IFN‑γ by bovine and ovine T cell subsets section” 
using antibodies listed in Table 3 and acquired using an LSRFortessa™ 
cell analyzer (Becton Dickenson). Cells were gated to eliminate dead 
cells using the Vioblue Live/Dead  Stain® Fixable Dead Cell Stain Kit, Side 
Scatter Height (SSC‑H) vs Vioblue channel (A) and to include only single 
cells Forward Scatter Height (FSC‑H) vs FSC‑Area (FSC‑A) (B). Gated single 
cells used for subsequent two‑colour cell phenotyping and intracellular 
cytokine staining (C). Quadrant region boundaries were set based on 
isotype‑matched directly conjugated antibody controls (FITC vs APC/
Alexafluor 647 channels, D) and (Phycoerythrin vs APC/Alexafluor 647 
channels, E) and fluorescence minus one (FMO) controls for each cell 
marker (WC‑1, F; CD4, G; CD8β, H) and for each cytokine IL‑17A, I‑J and 
IFN‑γ, K‑L). Data are shown for one representative animal of four.
Additional file 6. IL-17A sequence pair-wise identity matrix. BovIL‑
17‑A and ovIL‑17A cDNAs encoding the mature proteins were aligned 
with the corresponding sequences from a variety of vertebrates including 
representative mammal, reptile and avian species and the protein pair‑
wise identity matrix was derived using Clustal 2.1.
Additional file 7. Principal components analysis biplot of binding 
of commercial antibodies to transfected Chinese Hamster Ovary 
cells stably-expressing recombinant bovine or ovine IL-17A. A 
principal component analysis (PCA) was conducted to investigate the 
structure of relationships between commercial monoclonal antibody 
clones to IL‑17A and the six metrics used to assess antibody staining. 
These metrics were the binding to transfected CHO cells stably expressing 
rbovIL‑17A, rovIL‑17A or the untransfected CHO negative control (UTF) 
cells [numerical percentage of (%) cells] in the upper positive region (% 
CHO UTF, % bovIL‑17A and % ovIL‑17A) and delta median fluorescence 
intensity (deltaMFI) values for the same three CHO cell lines. Data used in 
the PCA is taken from Additional File 6. PCA reduced the dimension of the 
data set by means of optimal linear combinations (principal components, 
PCs) of the six metrics aimed to retain as much of the original data vari‑
ability as possible. The results were displayed using a correlation biplot 
based on the two first PCs (those accounting for the highest percentage 
of the total variability) to facilitate discussion and ranking of the com‑
mercial antibodies.
Additional file 8. Neutralisation of recombinant bovine and ovine 
IL-17A activity on ovine cells by commercial mab. Ovine ST‑6 cells 
were set up as described in “Bulk recombinant cytokine production and 
functional determination of recombinant bovine and ovine IL‑17A sec‑
tion” but using 96 well flat bottom plates. The following treatments were 
pre‑incubated at 37 °C for 2 h in a water bath: IMDM culture medium only 
(unstimulated cells), rovIL‑17A (50 ng/mL), rovIL‑17A (50 ng/mL) + MT504 
monoclonal antibody (mab, 1 μg/mL), rbovIL‑17A (50 ng/mL) and rbovIL‑
17A (50 ng/mL) + MT504 mab (1 μg/mL). The treatments were then 
added to the ovine cells for 24 h and harvested and assayed as previously 
described. The X‑axis displays the neutralisation bioassay treatments and 
the Y‑axis shows levels of CXCL8 in pg/mL. Data are the arithmetic mean 
of three technical replicate samples from one representative experiment 
of two. The percentage neutralisation values displayed on the graph have 
been calculated by firstly deducting the unstimulated (IMDM culture 
medium control) value from all other treatment values. The value for 
rbovIL‑17A neutralisation with MT504 mab was calculated by: 100 minus 
[(rbovIL‑17A/MT504 mab minus background value) divided by (rbovIL‑17A 
minus background value) multiplied by 100]. Percentage neutralisation for 
rovIL‑17A was calculated by substituting rbovIL‑17A for rovIL‑17A values 
into equation above.
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